Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of $270.42 million. The enterprise value is $243.96 million.
| Market Cap | 270.42M |
| Enterprise Value | 243.96M |
Important Dates
The last earnings date was Wednesday, April 24, 2024, after market close.
| Earnings Date | Apr 24, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Nanobiotix has 47.11 million shares outstanding. The number of shares has increased by 1.16% in one year.
| Shares Outstanding | 47.11M |
| Shares Change (YoY) | +1.16% |
| Shares Change (QoQ) | +1.02% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 19.69% |
| Float | 22.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 48.31 |
| PS Ratio | 6.72 |
| Forward PS | 3.46 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.75
| Current Ratio | 1.75 |
| Quick Ratio | 1.53 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.67 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -51.70% |
| Return on Capital (ROIC) | -54.96% |
| Revenue Per Employee | $394,412 |
| Profits Per Employee | -$432,462 |
| Employee Count | 102 |
| Asset Turnover | 0.47 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Nanobiotix has paid $128,466 in taxes.
| Income Tax | 128,466 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +125.54% in the last 52 weeks. The beta is 1.25, so Nanobiotix's price volatility has been higher than the market average.
| Beta (1Y) | 1.25 |
| 52-Week Price Change | +125.54% |
| 50-Day Moving Average | 6.30 |
| 200-Day Moving Average | 7.16 |
| Relative Strength Index (RSI) | 44.51 |
| Average Volume (30 Days) | 29,841 |
Short Selling Information
| Short Interest | 52,704 |
| Short Previous Month | 50,275 |
| Short % of Shares Out | 0.11% |
| Short % of Float | 0.23% |
| Short Ratio (days to cover) | 0.78 |
Income Statement
In the last 12 months, Nanobiotix had revenue of $40.23 million and -$44.11 million in losses. Loss per share was -$1.16.
| Revenue | 40.23M |
| Gross Profit | 38.76M |
| Operating Income | -28.67M |
| Pretax Income | -42.37M |
| Net Income | -44.11M |
| EBITDA | -24.91M |
| EBIT | -26.53M |
| Loss Per Share | -$1.16 |
Balance Sheet
The company has $80.59 million in cash and $54.13 million in debt, giving a net cash position of $26.46 million or $0.56 per share.
| Cash & Cash Equivalents | 80.59M |
| Total Debt | 54.13M |
| Net Cash | 26.46M |
| Net Cash Per Share | $0.56 |
| Equity / Book Value | -1.97M |
| Book Value Per Share | -0.04 |
| Working Capital | 40.11M |
Cash Flow
In the last 12 months, operating cash flow was -$13.36 million and capital expenditures -$360,775, giving a free cash flow of -$13.72 million.
| Operating Cash Flow | -13.36M |
| Capital Expenditures | -360,775 |
| Free Cash Flow | -13.72M |
| FCF Per Share | -$0.39 |
Margins
Gross margin is 96.35%, with operating and profit margins of -71.26% and -109.65%.
| Gross Margin | 96.35% |
| Operating Margin | -71.26% |
| Pretax Margin | -105.33% |
| Profit Margin | -109.65% |
| EBITDA Margin | -61.91% |
| EBIT Margin | -65.93% |
| FCF Margin | -34.10% |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.16% |
| Shareholder Yield | -1.16% |
| Earnings Yield | -16.31% |
| FCF Yield | -5.07% |
Analyst Forecast
The average price target for Nanobiotix is $11.00, which is 91.64% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.00 |
| Price Target Difference | 91.64% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 69.80% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nanobiotix has an Altman Z-Score of -3.13 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.13 |
| Piotroski F-Score | 3 |